Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587309 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
A Phase 3 study, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
NCT05587309 is a Phase 3 study that has completed, run by Braintree Laboratories. The registered enrollment target is 1,250 participants.
The verdict
NCT05587309, a Phase 3 study, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
Study Summary
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.
Interventions
- DRUG BLI5100
- DRUG PPI Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2022-10-30 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05587309
The ClinicalTrials.gov registry entry for NCT05587309 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BLI5100 is the first listed.
NCT05587309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05587309 about?
NCT05587309 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis". The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once dail...
What is the current status of trial NCT05587309?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2022-10-30. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT05587309?
The interventions under investigation include: BLI5100 (DRUG), PPI Control (DRUG).
Who is sponsoring clinical trial NCT05587309?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.